The GLP 1 Docket: Episode 1

GLP-1 compounding continues to be a focal point of regulatory scrutiny and industry excitement across the US, yet many pharmacists and patients are left to navigate the complex legal shift following the end of federal shortages. In this episode, hosts Lucas Morgan, Esq, and Dae Lee, PharmD, Esq, CPBS, shareholders at Buchanan Ingersoll & Rooney, discuss the rapidly evolving landscape of GLP-1 medications and the critical transition from "shortage-era" compounding to the current enforcement environment of 2026. In this conversation, they cover: - The Current Regulatory Climate: A look at the mid-2026 status of GLP-1 compounding following major announcements from the federal government and private sector giants like Novo Nordisk and Eli Lilly. - Defining GLP-1 Compounding: Understanding the distinctions between brand-name products (Wegovy, Mounjaro, and Ozempic) and those produced by 503A compounding pharmacies and 503B outsourcing facilities. - The "Shortage List" Catalyst: How the FDA shortage list historically allowed for the legal compounding of semaglutide and tirzepatide to fill market gaps. - The 2025 Pivot: Analysis of the FDA’s decision to remove these substances from the shortage list and what that means for the legality of compounding today. - FDA Approval vs. Compounding: Clarifying why compounded products lack FDA approval and how they differ from commercially available brand-name or generic drugs. - Enforcement and Exceptions: The role of the FDA and state boards of pharmacy in monitoring compounding and the very narrow exceptions that still allow for tailored drug regimens. - The Influence of Federal Figures: Discussing the impact of statements from key federal figureheads, including RFK Jr., on the future of the industry. If you are a pharmacist, health care provider, or industry stakeholder looking to understand the legal boundaries of weight-loss medication production, this podcast offers essential insights into the intersection of pharmacy practice and federal law.